This trial will test whether a biologic drug can improve brain plasticity and perception of well-being for people with psoriasis.
- Healthy Subjects
2 Primary · 7 Secondary · Reporting Duration: Baseline, Up to Week 4 (Visit 3)
Side Effects for
2 Treatment Groups
1 of 2
1 of 2
40 Total Participants · 2 Treatment Groups
Primary Treatment: Secukinumab · No Placebo Group · Phase 4
Who is running the clinical trial?
Age 18 - 65 · All Participants · 8 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
How old are they?
|18 - 65||100.0%|
What site did they apply to?
|University of Miami||100.0%|
What portion of applicants met pre-screening criteria?
|Did not meet criteria||50.0%|
Why did patients apply to this trial?
- "personal motivation and to help new effective treatments"
How many prior treatments have patients received?
Frequently Asked Questions
Does the research team accept younger individuals for this trial?
"This experiment necessitates that participants are aged between 18-65. Simultaneously, there are 86 trials available for minors and 537 clinical studies applicable to the elderly population." - Anonymous Online Contributor
Has Secukinumab gone through the necessary regulatory processes to be deemed safe for public consumption?
"Per our assessment, secukinumab is assessed to have a high degree of safety due it its Phase 4 trial status and concomitant approval for medical use." - Anonymous Online Contributor
Is there an opportunity for participants to join this research currently?
"Affirmative. Clinicaltrials.gov suggest that this examination is actively enrolling participants as of now, with the trial having been first posted on June 29th 2021 and most recently updated around September 2022. To meet their goals, they need to recruit 40 patients from 1 medical centre." - Anonymous Online Contributor
What are the fundamental aims of this trial?
"This clinical trial seeks to assess the alteration of gray matter density within a Baseline, Up to Week 4 (Visit 3) timeline. Secondary objectives include evaluation of itch intensity using NRS ratings ranging from 0-10, sleep quality measured via PSQI scores between 0 and 49, as well as pain levels appraised with an identical numerical rating system." - Anonymous Online Contributor
Would I be eligible to partake in this clinical research?
"This clinical trial is enrolling 40 qualified participants aged 18 to 65 years old, who suffer from psoriasis. To be eligible for the study they must meet the following prerequisites: no contraindications to MRI scanning as verified by an MRI technologist using a site-approved screening form; a body surface area (BSA) of more than 5% affected by psoriasis and evidence of TB test in past 8 months or willingness to undertake one; absence of chronic pain, itch, skin conditions and any neurological/psychiatric diseases; women with child bearing potential will require pregnancy testing prior to enrolment; English fluency both" - Anonymous Online Contributor
Are there any analogous experiments involving Secukinumab?
"Currently, 27 clinical trials are being conducted to evaluate the efficacy of secukinumab. Among them, 13 have advanced into Phase 3. The primary sites for such research are Brest and Buenos Aires; however, over a thousand locations around the world are offering this therapy as part of their own experiments." - Anonymous Online Contributor
What circumstances is Secukinumab typically prescribed for?
"Secukinumab has been clinically tested to treat ankylosing spondylitis, [psoriatic arthritis](https://www.withpower.com/clinical-trials/psoriatic-arthritis), and enthesitis related arthritis (ERA)." - Anonymous Online Contributor
What is the total enrollment of this experiment?
"Indeed, the data available on clinicaltrials.gov indicates that this medical trial is in a current search of participants. The first posting occurred on June 29th 2021 and has had its most recent update September 29th 2022. 40 patients need to be found over one site for recruitment purposes." - Anonymous Online Contributor